NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RLYB
Rallybio Corporation
There isn't enough reported data to score RLYB yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RLYB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| Strong | |
| Unavailable |
RLYB's cash flow is currently strong, and its profitability is stable, but its revenue is weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over RLYB in the historical PE scenario, which offers more potential upside but is not a forecast.
RLYB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $9.58 | -39% |
| Fair | 2.1x | $9.76 | -38% |
| Expensive | 2.9x | $13.40 | -14% |
| Current | 3.4x | $15.65 | — |
Historical ranges are pointers, not guarantees.
RLYB's PE is 3.4x, but its earnings don't support one, so it isn't a reliable read right now.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RLYB Forward outlook
There aren't enough analyst estimates for RLYB to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
RLYB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $4.56 | +$6.96 |
| Q2 2026 | $7.92 | +$15.28 |
| Q1 2026 | -$1.37 | +$7.19 |
| Q4 2025 | -$1.59 | +$9.05 |
| Q3 2025 | -$2.40 | +$10.40 |
| Q2 2025 | -$7.36 | +$6.96 |
| Q1 2025 | -$8.56 | +$6.48 |
| Q4 2024 | -$10.64 | +$4.08 |
RLYB has returned to profit: it earned $4.56 per share over the past year, after losing money the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over RLYB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RLYB on profitability, with a higher operating margin.
RLYB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $212K | 0% |
| Q4 2025 | $222K | +11000% |
| Q3 2025 | $212K | -29% |
| Q2 2025 | $212K | -29% |
RLYB's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -4119% | +442 points |
| Q4 2025 | -2888% | +577512 points |
| Q3 2025 | -3267% | +769 points |
| Q2 2025 | -4744% | +953 points |
| Q1 2025 | -4561% | N/A |
| Q4 2024 | -580400% | N/A |
| Q3 2024 | -4035% | N/A |
| Q2 2024 | -5697% | N/A |
RLYB's operating margin was −4119% last quarter, up 442 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
RLYB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$4.3M |
| Q2 2026 | $45.9M | +$54.3M |
| Q1 2026 | -$8M | +$2.2M |
| Q3 2025 | -$6.6M | +$7M |
| Q2 2025 | -$8.4M | +$2M |
| Q1 2025 | -$10.2M | +$5.3M |
| Q3 2024 | -$13.5M | +$2.9M |
| Q2 2024 | -$10.4M | +$3M |
RLYB has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over RLYB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RLYB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -82.9K shares |
| 1 year | +1.5% | +82.7K shares |
| 3 years | +13% | +649K shares |
| 5 years | +1049% | +5.2M shares |
| Available history | +106% | +2.9M shares |
RLYB has 6M diluted shares, up 1.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RLYB Net Leverage
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RLYB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.4 | Neutral |
| Stochastic | 17.7 | Oversold |
RLYB's weekly RSI is 54 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RLYB PE vs Healthcare Sector
| Metric | RLYB | Sector median | Relative |
|---|---|---|---|
| PE | 3.4x | 26x | 87% below |
RLYB has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RLYB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.3 | 4.1% below |
| 20 week MA | $16.4 | 4.7% below |
| 50 week MA | $12.1 | 29% above |
| 100 week MA | $8.34 | 88% above |
| 200 week MA | $17.4 | 10% below |
RLYB has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
RLYB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $136.0 | $91.6 | -33% |
| 2022 | $91.6 | $46.0 | -50% |
| 2023 | $46.0 | $19.1 | -58% |
| 2024 | $19.1 | $7.31 | -62% |
| 2025 | $7.31 | $5.50 | -25% |
| 2026 YTD | $5.50 | $15.7 | +185% |
RLYB has the edge over NVO on returns for 2026, with the stronger performance.